Ryan Scott

Articles

Investigators Seek to Evaluate Obe-Cel’s Role in Relapsed/Refractory B-Cell ALL

March 03, 2022

An expert with Moffitt Cancer Center comments on the ongoing FELIX trial, and the potential of the novel CAR T-cell therapy, obecabtagene autoleucel, to change the B-cell acute lymphoblastic leukemia treatment paradigm.